MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients

BMC Medical Genomics

Volumn 3, Issue , 2010, Pages

  MacDermed, Dhara M ^a   Khodarev, Nikolai N ^b   Pitroda, Sean P ^b   Edwards, Darrin C ^c   Pelizzari, Charles A ^b   Huang, Lei ^d   Kufe, Donald W ^d   Weichselbaum, Ralph R ^b  

^a SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 20; CELL DIVISION CYCLE 2 PROTEIN; CELL PROTEIN; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 3; MITOTIC ARREST DEFICIENT LIKE 1 PROTEIN; MUCIN 1; PROTEIN MAD2; PROTEIN MAD2L1; PROTEIN REGULATOR OF CYTOKINESIS 1; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; UNCLASSIFIED DRUG; TUMOR MARKER;

ANIMAL CELL; ARTICLE; CANCER SURVIVAL; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; HUMAN; LUNG ADENOCARCINOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RAT; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; ANIMAL; CELL LINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; TREATMENT OUTCOME;

ADENOCARCINOMA; ANIMALS; CELL LINE; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MUCIN-1; RATS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77951791725     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-3-16     Document Type: Article

References (42)

1. Cancer statistics, 2004. A Jemal RC Tiwari T Murray A Ghafoor A Samuels E Ward EJ Feuer MJ Thun, CA Cancer J Clin 2004 54 1 8 29 10.3322/canjclin.54.1.8 14974761
2. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. R Govindan N Page D Morgensztern W Read R Tierney A Vlahiotis EL Spitznagel J Piccirillo, J Clin Oncol 2006 24 28 4539 4544 10.1200/JCO.2005.04. 4859 17008692
3. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. A Auperin C Le Pechoux JP Pignon C Koning B Jeremic G Clamon L Einhorn D Ball MG Trovo HJ Groen,, et al. Ann Oncol 2006 17 3 473 483 10.1093/annonc/mdj117 16500915
4. A 15-gene expression signature prognostic for survival and predictive for adjuvant chemotherapy benefit in JBR.10 patients. MS Tsao C Zhu K Ding D Strumpf M Pintilie M Meyerson L Seymour I Jurisica FA Shepherd, J Clin Oncol 2008 26 (May 20 suppl; abstr 7510)
5. A five-gene signature and clinical outcome in non-small-cell lung cancer. HY Chen SL Yu CH Chen GC Chang CY Chen A Yuan CL Cheng CH Wang HJ Terng SF Kao,, et al. N Engl J Med 2007 356 1 11 20 10.1056/NEJMoa060096 17202451
6. Pattern of mucin gene expression in normal and neoplastic lung tissues. E Seregni C Botti C Lombardo A Cantoni A Bogni I Cataldo E Bombardieri, Anticancer Res 1996 16 4B 2209 2213 8694545
7. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Y Li D Liu D Chen S Kharbanda D Kufe, Oncogene 2003 22 38 6107 6110 10.1038/sj.onc.1206732 12955090
8. MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. L Huang J Ren D Chen Y Li S Kharbanda D Kufe, Cancer Biol Ther 2003 2 6 702 706 14688481
9. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. L Yin Y Li J Ren H Kuwahara D Kufe, J Biol Chem 2003 278 37 35458 35464 10.1074/jbc.M301987200 12826677
10. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. J Ren N Agata D Chen Y Li WH Yu L Huang D Raina W Chen S Kharbanda D Kufe, Cancer Cell 2004 5 2 163 175 10.1016/S1535-6108(04)00020-0 14998492
11. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. D Raina S Kharbanda D Kufe, J Biol Chem 2004 279 20 20607 20612 10.1074/jbc.M310538200 14999001
12. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. X Wei H Xu D Kufe, Cancer Cell 2005 7 2 167 178 10.1016/j.ccr.2005.01.008 15710329
13. MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. A Ohgami T Tsuda T Osaki T Mitsudomi Y Morimoto T Higashi K Yasumoto, Ann Thorac Surg 1999 67 3 810 814 10.1016/S0003-4975(99)00041-7 10215233
14. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. F Guddo A Giatromanolaki MI Koukourakis C Reina AM Vignola G Chlouverakis J Hilkens KC Gatter AL Harris G Bonsignore, J Clin Pathol 1998 51 9 667 671 10.1136/jcp.51.9.667 9930070
15. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC). NN Khodarev Y Kataoka JS Murley RR Weichselbaum DJ Grdina, Int J Radiat Oncol Biol Phys 2004 60 2 553 563 15380592
16. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. RR Weichselbaum H Ishwaran T Yoon DS Nuyten SW Baker N Khodarev AW Su AY Shaikh P Roach B Kreike,, et al. Proc Natl Acad Sci USA 2008 105 47 18490 18495 10.1073/pnas.0809242105 19001271
17. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. SP Pitroda NN Khodarev MA Beckett DW Kufe RR Weichselbaum, Proc Natl Acad Sci USA 2009 106 14 5837 5841 10.1073/pnas.0812029106 19289846
18. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. NN Khodarev SP Pitroda MA Beckett DM MacDermed L Huang DW Kufe RR Weichselbaum, Cancer Res 2009 69 7 2833 2837 10.1158/0008-5472.CAN-08-4513 19318547
19. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. L Huang D Chen D Liu L Yin S Kharbanda D Kufe, Cancer Res 2005 65 22 10413 10422 10.1158/0008-5472.CAN-05- 2474 16288032
20. Method of RNA purification from endothelial cells for DNA array experiments. NN Khodarev J Yu E Nodzenski JS Murley Y Kataoka CK Brown DJ Grdina RR Weichselbaum, Biotechniques 2002 32 2 316, 318, 320 11848408
21. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. ET Kimchi MC Posner JO Park TE Darga M Kocherginsky T Karrison J Hart KD Smith JJ Mezhir RR Weichselbaum,, et al. Cancer Res 2005 65 8 3146 3154 15833844
22. Receiver operating characteristic analysis: a general tool for DNA array data filtration and performance estimation. NN Khodarev J Park Y Kataoka E Nodzenski S Hellman B Roizman RR Weichselbaum CA Pelizzari, Genomics 2003 81 2 202 209 10.1016/S0888-7543(02)00042-3 12620398
23. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. K Shedden JM Taylor SA Enkemann MS Tsao TJ Yeatman WL Gerald S Eschrich I Jurisica TJ Giordano DE Misek,, et al. Nat Med 2008 14 8 822 827 10.1038/nm.1790 18641660
24. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. A Bhattacharjee WG Richards J Staunton C Li S Monti P Vasa C Ladd J Beheshti R Bueno M Gillette,, et al. Proc Natl Acad Sci USA 2001 98 24 13790 13795 10.1073/pnas.191502998 11707567
25. Gene-expression profiles predict survival of patients with lung adenocarcinoma. DG Beer SL Kardia CC Huang TJ Giordano AM Levin DE Misek L Lin G Chen TG Gharib DG Thomas,, et al. Nat Med 2002 8 8 816 824 12118244
26. Basic principles of ROC analysis. CE Metz, Seminars in Nuclear Medicine 1978 VIII 4 283 298 10.1016/S0001-2998(78)80014-2
27. "Proper" Binormal ROC Curves: Theory and Maximum-Likelihood Estimation. CE Metz X Pan, J Math Psychol 1999 43 1 1 33 10.1006/jmps.1998.1218 10069933
28. Cdc20: a WD40 activator for a cell cycle degradation machine. H Yu, Mol Cell 2007 27 1 3 16 10.1016/j.molcel.2007.06.009 17612486
29. Essential roles of KIF4 and its binding partner PRC1 in organized central spindle midzone formation. Y Kurasawa WC Earnshaw Y Mochizuki N Dohmae K Todokoro, EMBO J 2004 23 16 3237 3248 10.1038/sj.emboj.7600347 15297875
30. Study of the higher eukaryotic gene function CDK2 using fission yeast. J Paris P Leplatois P Nurse, J Cell Sci 1994 107 Pt 3 615 623 8006075
31. Positive feedback sharpens the anaphase switch. LJ Holt AN Krutchinsky DO Morgan, Nature 2008 454 7202 353 357 10.1038/nature07050 18552837
32. Dual-specificity phosphatases: critical regulators with diverse cellular targets. KI Patterson T Brummer PM O'Brien RJ Daly, Biochem J 2009 418 3 475 489 19228121
33. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. R Kittler G Putz L Pelletier I Poser AK Heninger D Drechsel S Fischer I Konstantinova B Habermann H Grabner,, et al. Nature 2004 432 7020 1036 1040 10.1038/nature03159 15616564
34. A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. SH Dairkee Y Ji Y Ben DH Moore Z Meng SS Jeffrey, BMC Genomics 2004 5 1 47 10.1186/1471-2164-5-47 15260889
35. Gene expression profiles reveal an upregulation of E2F and downregulation of interferon targets by HPV18 but no changes between keratinocytes with integrated or episomal viral genomes. B Karstensen S Poppelreuther M Bonin M Walter T Iftner F Stubenrauch, Virology 2006 353 1 200 209 10.1016/j.virol.2006. 05.030 16814354
36. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition. D Tedesco J Zhang L Trinh G Lalehzadeh R Meisner KD Yamaguchi DL Ruderman H Dinter DA Zajchowski, Neoplasia 2007 9 7 601 613 10.1593/neo.07385 17710163
37. Bromodomain 4 activation predicts breast cancer survival. NP Crawford J Alsarraj L Lukes RC Walker JS Officewala HH Yang MP Lee K Ozato KW Hunter, Proc Natl Acad Sci USA 2008 105 17 6380 6385 10.1073/pnas.0710331105 18427120
38. Common markers of proliferation. ML Whitfield LK George GD Grant CM Perou, Nat Rev Cancer 2006 6 2 99 106 10.1038/nrc1802 16491069
39. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. DR Rhodes J Yu K Shanker N Deshpande R Varambally D Ghosh T Barrette A Pandey AM Chinnaiyan, Proc Natl Acad Sci USA 2004 101 25 9309 9314 10.1073/pnas.0401994101 15184677
40. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. YW Zhang TL Jones SE Martin NJ Caplen Y Pommier, J Biol Chem 2009 284 27 18085 18095 10.1074/jbc.M109.003020 19416980
41. Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells. D Raina R Ahmad MD Joshi L Yin Z Wu T Kawano B Vasir D Avigan S Kharbanda D Kufe, Cancer Res 2009 5133 5141 10.1158/0008-5472.CAN-09-0854 19491255
42. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. WC Cho, Biomed Pharmacother 2007 61 9 515 519 10.1016/j.biopha.2007.08.005 17913444